baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Emergent BioSolutions Inc/ US29089Q1058 /

5/30/2024 9:59:59 PM	Chg. +0.45	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
5.09USD	+9.70%	19,150 Turnover: 95,391.34	-Bid Size: -	-Ask Size: -	266.73 mill.USD	-	-

GlobeNewswire 5/10 Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024

GlobeNewswire 5/6 The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conferenc...

GlobeNewswire 5/1 Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

GlobeNewswire 5/1 Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Acces...

GlobeNewswire 4/30 Emergent BioSolutions Announces Amendment to its Existing Credit Facility

GlobeNewswire 4/22 Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on M...

GlobeNewswire 4/8 XORTX Welcomes New Member to the Board of Directors

GlobeNewswire 4/1 Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

GlobeNewswire 3/28 Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray...

GlobeNewswire 3/26 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

GlobeNewswire 3/25 Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

GlobeNewswire 3/20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook

GlobeNewswire 2/29 Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conf...

GlobeNewswire 2/29 Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update

GlobeNewswire 2/21 Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

GlobeNewswire 1/11 Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (...

GlobeNewswire 1/9 Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11,...

GlobeNewswire 11/28/2023 Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ ...

GlobeNewswire 11/24/2023 Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing

GlobeNewswire 11/8/2023 Emergent BioSolutions Reports Third Quarter 2023 Financial Results

GlobeNewswire 10/30/2023 UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference...

GlobeNewswire 10/19/2023 Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on...

GlobeNewswire 10/2/2023 Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

GlobeNewswire 9/20/2023 SHAREHOLDER ALERT: Morris Kandinov Investigating EBS, JRVR, EGIO, and HAFC; Shareholders are Encoura...

GlobeNewswire 9/13/2023 Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Developm...

Emergent BioSolutions Inc/ US29089Q1058 /

If you wish to receive reply to your feedback, please provide your email address.